Formosa Laboratories
台耀化學股份有限公司
Formosa Laboratories is a Taiwan TWSE-listed biotechnology company; its most advanced asset is Eribulin Injectable (Marketing authorization obtained; shipments started, Cancer), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| Eribulin Injectable | — | Marketing authorization obtained; shipments started | Cancer | United States | 2026-08-14 | Company disclosure |
Key events
No verified events in the past twelve months.